William Blair Comments on Pyxis Oncology Q1 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Research analysts at William Blair issued their Q1 2025 EPS estimates for Pyxis Oncology in a report released on Tuesday, March 18th. William Blair analyst A. Hsieh expects that the company will post earnings of ($0.32) per share for the quarter. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. William Blair also issued estimates for Pyxis Oncology’s Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.26) EPS and FY2026 earnings at ($1.32) EPS.

Other equities research analysts also recently issued reports about the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $8.00 target price on shares of Pyxis Oncology in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Pyxis Oncology in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Pyxis Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $9.20.

Pyxis Oncology Stock Performance

PYXS stock opened at $1.21 on Friday. The stock has a fifty day moving average of $1.33 and a 200-day moving average of $2.35. Pyxis Oncology has a fifty-two week low of $0.99 and a fifty-two week high of $6.18. The company has a market capitalization of $74.52 million, a price-to-earnings ratio of -1.17 and a beta of 1.11.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.01. The firm had revenue of $16.15 million for the quarter.

Institutional Investors Weigh In On Pyxis Oncology

Institutional investors and hedge funds have recently modified their holdings of the company. MetLife Investment Management LLC increased its holdings in Pyxis Oncology by 41.1% during the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after acquiring an additional 5,484 shares during the period. Bank of America Corp DE lifted its position in Pyxis Oncology by 20.3% during the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock valued at $84,000 after purchasing an additional 9,062 shares during the last quarter. Commonwealth Equity Services LLC boosted its holdings in shares of Pyxis Oncology by 61.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company’s stock worth $41,000 after purchasing an additional 10,000 shares in the last quarter. Barclays PLC grew its holdings in shares of Pyxis Oncology by 20.2% during the 4th quarter. Barclays PLC now owns 77,013 shares of the company’s stock valued at $121,000 after purchasing an additional 12,924 shares during the last quarter. Finally, Jane Street Group LLC boosted its position in Pyxis Oncology by 40.8% during the third quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock valued at $182,000 after buying an additional 14,349 shares during the period. 39.09% of the stock is owned by hedge funds and other institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.